349 related articles for article (PubMed ID: 23147197)
61. [Targeted epigenetic therapy of cancer. Achievements and perspectives].
Valdespino-Gómez VM; Valdespino-Castillo VE
Cir Cir; 2012; 80(5):470-80. PubMed ID: 23351455
[TBL] [Abstract][Full Text] [Related]
62. The Hedgehog pathway as a drug target in cancer therapy.
Lauth M; Toftgård R
Curr Opin Investig Drugs; 2007 Jun; 8(6):457-61. PubMed ID: 17621875
[TBL] [Abstract][Full Text] [Related]
63. SOX2 in cancer stemness: tumor malignancy and therapeutic potentials.
Mamun MA; Mannoor K; Cao J; Qadri F; Song X
J Mol Cell Biol; 2020 Feb; 12(2):85-98. PubMed ID: 30517668
[TBL] [Abstract][Full Text] [Related]
64. c-MET kinase inhibitors: a patent review (2011 - 2013).
Zhu K; Kong X; Zhao D; Liang Z; Luo C
Expert Opin Ther Pat; 2014 Feb; 24(2):217-30. PubMed ID: 24266843
[TBL] [Abstract][Full Text] [Related]
65. Novel GC-rich DNA-binding compound produced by a genetically engineered mutant of the mithramycin producer Streptomyces argillaceus exhibits improved transcriptional repressor activity: implications for cancer therapy.
Albertini V; Jain A; Vignati S; Napoli S; Rinaldi A; Kwee I; Nur-e-Alam M; Bergant J; Bertoni F; Carbone GM; Rohr J; Catapano CV
Nucleic Acids Res; 2006; 34(6):1721-34. PubMed ID: 16571899
[TBL] [Abstract][Full Text] [Related]
66. Advances and challenges in targeting FGFR signalling in cancer.
Babina IS; Turner NC
Nat Rev Cancer; 2017 May; 17(5):318-332. PubMed ID: 28303906
[TBL] [Abstract][Full Text] [Related]
67. The role of DNA-demethylating agents in cancer therapy.
Mehdipour P; Murphy T; De Carvalho DD
Pharmacol Ther; 2020 Jan; 205():107416. PubMed ID: 31626871
[TBL] [Abstract][Full Text] [Related]
68. Regulation of the PML tumor suppressor in drug-induced senescence of human normal and cancer cells by JAK/STAT-mediated signaling.
Hubackova S; Novakova Z; Krejcikova K; Kosar M; Dobrovolna J; Duskova P; Hanzlikova H; Vancurova M; Barath P; Bartek J; Hodny Z
Cell Cycle; 2010 Aug; 9(15):3085-99. PubMed ID: 20699642
[TBL] [Abstract][Full Text] [Related]
69. Molecular Pharmacology of Malignant Pleural Mesothelioma: Challenges and Perspectives From Preclinical and Clinical Studies.
Thellung S; Favoni RE; Würth R; Nizzari M; Pattarozzi A; Daga A; Florio T; Barbieri F
Curr Drug Targets; 2016; 17(7):824-49. PubMed ID: 26240051
[TBL] [Abstract][Full Text] [Related]
70. Targeting Translation of mRNA as a Therapeutic Strategy in Cancer.
Pal I; Safari M; Jovanovic M; Bates SE; Deng C
Curr Hematol Malig Rep; 2019 Aug; 14(4):219-227. PubMed ID: 31231778
[TBL] [Abstract][Full Text] [Related]
71. Pseudogenes as Biomarkers and Therapeutic Targets in Human Cancers.
Sisu C
Methods Mol Biol; 2021; 2324():319-337. PubMed ID: 34165724
[TBL] [Abstract][Full Text] [Related]
72. From correlation to causality: microarrays, cancer, and cancer treatment.
O'Neill GM; Catchpoole DR; Golemis EA
Biotechniques; 2003 Mar; Suppl():64-71. PubMed ID: 12664688
[No Abstract] [Full Text] [Related]
73. Targeting the hedgehog pathway: role in cancer and clinical implications of its inhibition.
Cohen DJ
Hematol Oncol Clin North Am; 2012 Jun; 26(3):565-88, viii. PubMed ID: 22520980
[TBL] [Abstract][Full Text] [Related]
74. Small-molecule inhibitors targeting the DNA-binding domain of STAT3 suppress tumor growth, metastasis and STAT3 target gene expression in vivo.
Huang W; Dong Z; Chen Y; Wang F; Wang CJ; Peng H; He Y; Hangoc G; Pollok K; Sandusky G; Fu XY; Broxmeyer HE; Zhang ZY; Liu JY; Zhang JT
Oncogene; 2016 Feb; 35(6):783-92. PubMed ID: 26073084
[TBL] [Abstract][Full Text] [Related]
75. Gene expression signature of human cancer cell lines treated with the ras inhibitor salirasib (S-farnesylthiosalicylic acid).
Blum R; Elkon R; Yaari S; Zundelevich A; Jacob-Hirsch J; Rechavi G; Shamir R; Kloog Y
Cancer Res; 2007 Apr; 67(7):3320-8. PubMed ID: 17409441
[TBL] [Abstract][Full Text] [Related]
76. Inhibiting Heat Shock Factor 1 in Cancer: A Unique Therapeutic Opportunity.
Dong B; Jaeger AM; Thiele DJ
Trends Pharmacol Sci; 2019 Dec; 40(12):986-1005. PubMed ID: 31727393
[TBL] [Abstract][Full Text] [Related]
77. Epigenetic/Genetic Mismatch: Using Transdifferentiation as a Potential Cancer Therapy to Exploit the Cell Type Specificity of Cancer.
Mendelsohn AR; Lei JL; Chatterjee D
Crit Rev Oncog; 2015; 20(5-6):519-35. PubMed ID: 27279245
[TBL] [Abstract][Full Text] [Related]
78. Signal transduction pathways regulating cyclooxygenase-2 expression: potential molecular targets for chemoprevention.
Chun KS; Surh YJ
Biochem Pharmacol; 2004 Sep; 68(6):1089-100. PubMed ID: 15313405
[TBL] [Abstract][Full Text] [Related]
79. Epigenetically Active Drugs Inhibiting DNA Methylation and Histone Deacetylation.
Chistiakov DA; Myasoedova VA; Orekhov AN; Bobryshev YV
Curr Pharm Des; 2017; 23(8):1167-1174. PubMed ID: 27774908
[TBL] [Abstract][Full Text] [Related]
80. Epigenetic mechanism of survivin dysregulation in human cancer.
Lyu H; Huang J; He Z; Liu B
Sci China Life Sci; 2018 Jul; 61(7):808-814. PubMed ID: 29318497
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
